Published in J Rheumatol on November 01, 2008
Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea. JAMA Dermatol (2013) 1.51
Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine (2011) 0.98
Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am (2012) 0.96
Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort. Arthritis Rheumatol (2014) 0.79
Plaque morphea with neurological involvement—an extraordinary uncommon presentation. Clin Rheumatol (2013) 0.76
Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study. J Am Acad Dermatol (2013) 0.76
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum (2015) 0.75
Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients. Br J Dermatol (2014) 0.75
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75
Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol (2017) 0.75
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum (2003) 1.94
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol (2006) 1.85
Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum (2004) 1.82
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis (2007) 1.66
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol (2005) 1.66
Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol (2006) 1.64
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53
Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) (2012) 1.41
Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum (2003) 1.37
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol (2009) 1.35
Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum (2005) 1.31
Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol (2004) 1.29
Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum (2007) 1.28
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) (2009) 1.23
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum (2007) 1.23
Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol (2008) 1.22
Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum (2005) 1.18
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis (2010) 1.18
Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol (2005) 1.18
Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum (2009) 1.16
Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum (2003) 1.15
A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum (2003) 1.14
Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol (2009) 1.13
Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol (2007) 1.10
Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis (2013) 1.10
Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum (2009) 1.08
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken) (2012) 1.06
Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum (2007) 1.05
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) (2014) 1.03
Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum (2009) 1.03
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum (2006) 1.03
Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum (2009) 1.03
A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum (2012) 1.02
Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum (2009) 0.99
Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun (2007) 0.99
Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum (2013) 0.98
Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol (2008) 0.97
Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum (2012) 0.96
Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol (2007) 0.94
Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis (2007) 0.90
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum (2005) 0.90
Scleroderma renal crisis: a pathology perspective. Int J Rheumatol (2010) 0.87
Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) (2014) 0.86
Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol (2004) 0.85
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum (2004) 0.85
Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology (Oxford) (2011) 0.84
Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol (2012) 0.83
Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. Clin Exp Rheumatol (2010) 0.82
HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (Oxford) (2009) 0.82
Quality indicator set for systemic sclerosis. Clin Exp Rheumatol (2011) 0.81
Muscle cramps associated with localized scleroderma skin lesions: focal dystonia, neuromyotonia, or nerve entrapment? J Rheumatol (2006) 0.81
Connective tissue diseases: Predicting death in SSc: planning and cooperation are needed. Nat Rev Rheumatol (2011) 0.80
Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. Rheumatology (Oxford) (2009) 0.80
Myasthenia gravis and scleroderma: two cases and a review of the literature. Clin Neurol Neurosurg (2007) 0.80
Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis. Arthritis Res Ther (2013) 0.79
Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol (2005) 0.78
T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun (2006) 0.78
A novel protein highly expressed in testis is overexpressed in systemic sclerosis fibroblasts and targeted by autoantibodies. J Immunol (2003) 0.77
Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken) (2013) 0.77
Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol (2004) 0.77
Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol (2014) 0.76
Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. Rheumatology (Oxford) (2013) 0.76
Commentary on myofascial release therapy in systemic lupus erythematosus and scleroderma. J Bodyw Mov Ther (2011) 0.75
Scleroderma renal crisis: a high index of suspicion speeds diagnosis and life-saving treatment. South Med J (2006) 0.75
Dr Leroy's contribution to the understanding of systemic sclerosis. Clin Exp Rheumatol (2004) 0.75